Matt Larew

Stock Analyst at William Blair

(0.04)
# 4,338
Out of 4,818 analysts
12
Total ratings
14.29%
Success rate
-30.58%
Average return

Stocks Rated by Matt Larew

Maravai LifeSciences Holdings
Nov 8, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $2.11
Upside: -
Amedisys
Jul 1, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $93.64
Upside: -
Ginkgo Bioworks Holdings
May 10, 2024
Downgrades: Underperform
Price Target: n/a
Current: $7.59
Upside: -
AptarGroup
Apr 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $148.67
Upside: -
Bio-Techne
Aug 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $50.18
Upside: -
Avantor
Jul 31, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $15.50
Upside: -
InnovAge Holding
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $2.91
Upside: -
MaxCyte
Aug 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.82
Upside: -
Twist Bioscience
Jun 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $37.62
Upside: -